摘要
目的:观察尼莫地平治疗预防缺血性脑血管事件所引起的认知障碍中的临床效果。方法:将在我院进行治疗的120例缺血性脑血管事件患者随机分为观察组60例和对照组60例。对照组患者按照常规方法进行治疗,观察组患者在此基础上给予尼莫地平治疗,观察对比两组的治疗效果。结果:观察组总有效率显著高于对照组,差异具有统计学意义(P<0.05)。两组患者治疗后MOCA评分和MMSE评分均随着治疗时间的延长而逐渐增加。对照组患者治疗2个月及3个月后MOCA评分与治疗前比较,差异具有统计学意义(P<0.05);观察组治疗1个月后MOCA评分与治疗前比较,差异具有统计学意义(P<0.05)。观察组每月治疗后MOCA评分显著高于对照组,差异具有统计学意义(P<0.05)。两组患者治疗2个月及3个月后MMSE评分与治疗前比较,差异具有统计学意义(P<0.05)。观察组患者治疗3个月后MMSE评分显著高于对照组,差异具有统计学意义(P<0.05)。随访1年后,观察组MMSS、MOCA评分均显著高于对照组,差异均具有统计学意义(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论:尼莫地平对于缺血性脑血管事件所引起的认知障碍的预防有较好疗效,安全性良好,值得推广应用。
Objective： To observe the clinical effect of nimodipine in the prevention of cognitive impairment caused by ischemic cerebrovascular events. Methods： 120 cases of ischemic cerebral vascular events in our hospital were randomly divided into observation group and control group, 60 cases in each group. The control group was treated with conventional method, and the observation group was given nimodipine treatment based on the control group, and the therapeutic effect of the two groups were observed and compared. Results： The total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant （P〈0.05）. The MOCA score and MMSE score of two groups were gradually increased with the extension of treatment time after treatment. After 2 months and 3 months later, the difference of MOCA score in the control group was statistically significant compared with before treatment （P〈0.05）; and of compared with the treatment before treatment, the difference of the MOCA score in the observation group after 1 months was statistically significant compared with before treatment （]？〈0.05）. The MOCA score of the observation group was significantly higher than that in the control group after the treatment, and the difference was statistically significant （P〈0.05）. After 2 months and 3 months later, the difference of MMSE score in two groups was statistically significant compared with before treatment （P〈0.05） After 3 months of treatment, the MMSE score of the observation group was significantly higher than that in the control group, and the difference was statistically significant （P〈0.05）. After 1 years of follow-up, the MOCA score and MMSS score of observation group were significantly higher than the control group, the difference was statistically significant （P〈0.05）. No serious adverse reactions occurred during the treatment of the two groups. Conclusion： Nimodipine has good effect and safety on the prevention of cognitive impairment caused by ischemic cerebrovascular events.
出处
《现代生物医学进展》
CAS
2016年第24期4690-4692,4708,共4页
Progress in Modern Biomedicine
关键词
尼莫地平
缺血性脑血管事件
认知障碍
Nimodipine
Ischemic cerebrovascular events
Cognitive impairment
